<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357681</url>
  </required_header>
  <id_info>
    <org_study_id>2010-023941-31</org_study_id>
    <nct_id>NCT01357681</nct_id>
  </id_info>
  <brief_title>Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)</brief_title>
  <acronym>ETON</acronym>
  <official_title>Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huntington's disease (HD) is an inherited autosomal dominant, progressive neurodegenerative
      disease. Clinically, HD is characterized by a triad of movement disorders, cognitive
      impairments and psychiatric disturbances. These symptoms represent a tremendous burden for
      patients and caregivers. HD is a fatal disorder with neither cure, nor evidence-based
      standard therapy available.

      The green tea polyphenon (2)-epigallocatechin-3-gallate (EGCG) was shown to have beneficial
      effects in cell and animal models of HD. The aim of this study is to evaluate the efficacy
      and tolerability of EGCG in HD.

      The investigators hypothesize that Sunphenon EGCG administered at a maximal daily dose of
      1200 mg compared to placebo during a period of 12 months improves cognition in patients with
      HD. As primary outcome measure, the change of cognitive functions (as measured by the Unified
      Huntington's Disease Rating Scale (UHDRS)-Cognition composite score of Stroop test, Verbal
      fluency &amp; Symbol Digit Modalities Test) after 12 months in comparison to Baseline was
      defined.

      The investigators further expect a positive influence of EGCG on other clinical
      manifestations of HD, measurable effects of EGCG on HD biomarkers and good safety and
      tolerability of EGCG in HD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of cognitive functions (UHDRS-Cognition: composite score of Stroop test, Verbal fluency &amp; Symbol Digit Modalities Test) after 12 months in comparison to baseline</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UHDRS Motor Score</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UHDRS Behavioural Score</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UHDRS Functional Assessment</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UHDRS Total Functional Capacity (TFC)</measure>
    <time_frame>Screening, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression: Beck Depression Inventory (BDI)</measure>
    <time_frame>Screening, Month 1, Month 2, Month 3, Month 6, Month 9, Month12, Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life: Short Form (36) Health Survey (SF-36)</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Well-Being: Satisfaction With Life Scale (SWLS)</measure>
    <time_frame>Month 0, Month 12, Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affective Processing: Positive and Negative Affect Schedule (PANAS)</measure>
    <time_frame>Month 0, Month 12, Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tonic and phasic Alertness</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Cognition: Mini Mental State Examination</measure>
    <time_frame>Screening, Month 12, Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative evaluation of motor functions: Qmotor</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy: assessed by magnetic resonance imaging (MRI)-voxel-based morphometry (VBM)</measure>
    <time_frame>Month 0, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and tolerability of EGCG</measure>
    <time_frame>Month 1 - Month 12</time_frame>
    <description>assessment of side effects and determination of blood and cerebrospinal fluid (CSF) levels of EGCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of huntingtin expression levels</measure>
    <time_frame>Screening - Month 13</time_frame>
    <description>Quantification of huntingtin in blood and CSF (optional)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>(2)-epigallocatechin-3-gallate (EGCG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(2)-epigallocatechin-3-gallate (EGCG)</intervention_name>
    <description>Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)</description>
    <arm_group_label>(2)-epigallocatechin-3-gallate (EGCG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chorea Huntington (CAG repeats &gt;39)

          -  UHDRS TFC &gt;5

          -  ≥18 years of age

          -  Readiness and ability to take oral medication

          -  Normal liver function laboratory test

          -  Stable concomitant medication regimen &gt; 4 weeks prior to Baseline

          -  Motivation for women with childbearing potential to use highly efficient contraception

        Exclusion Criteria:

          -  Clinically relevant abnormal findings in the ECG, vital signs, physical examination or
             laboratory values at Screening,

          -  Long-term treatment with potentially hepatoxic medication

          -  Any unstable medical condition

          -  BDI Depression score &gt; 9 AND clinical diagnosis of depression

          -  Suicidal tendencies

          -  Cognitive dysfunction defined as a score &lt; 23 in the Mini-Mental State Examination
             (MMSE) at Screening

          -  Liver or renal disease

          -  Schizophreniform psychosis within the last 6 months before baseline

          -  Consumption of more than two cups of black tea per day, consumption of green tea,
             consumption of &gt; 500 ml /day of grapefruit juice

          -  Participation in other Arzneimittelgesetz (AMG) or Medizinproduktegesetz (MPG) studies
             (three months before and during participation)

          -  Pregnancy/ lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Priller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neuropsychiatry, Charité Universitätsmedizin Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neuropsychiatry</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Josef Priller</investigator_full_name>
    <investigator_title>Prof. Dr. med; Director, Department of Neuropsychiatry</investigator_title>
  </responsible_party>
  <keyword>Huntington Disease</keyword>
  <keyword>Cognition</keyword>
  <keyword>Motor</keyword>
  <keyword>Behaviour</keyword>
  <keyword>Functional Capacity</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Biomarker</keyword>
  <keyword>MRI</keyword>
  <keyword>Huntingtin</keyword>
  <keyword>EGCG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

